

W James Morris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9360576/publications.pdf>

Version: 2024-02-01

23
papers

1,433
citations

567281

15
h-index

642732

23
g-index

23
all docs

23
docs citations

23
times ranked

1446
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate brachytherapy intraoperative dosimetry using a combination of radiographic seed localization with a C-arm and deformed ultrasound prostate contours. <i>Brachytherapy</i> , 2020, 19, 589-598.	0.5	2
2	Using a surgical prostate-specific antigen threshold of $>0.2 \text{ ng/mL}$ to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial. <i>Brachytherapy</i> , 2018, 17, 837-844.	0.5	29
3	ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 286-295.	0.8	250
4	ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 581-589.	0.8	85
5	In Reply to Hamstra et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 482.	0.8	3
6	In Regard to Ciezki et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 240-242.	0.8	1
7	Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the IJRTQ11) Overlapped with a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 275-285.	0.8	606
8	Focal application of low-dose-rate brachytherapy for prostate cancer: a pilot study. <i>Journal of Contemporary Brachytherapy</i> , 2017, 3, 197-208.	0.9	18
9	Robustness to source displacement in dual air kerma strength planning for focal low-dose-rate brachytherapy of prostate cancer. <i>Brachytherapy</i> , 2016, 15, 642-649.	0.5	3
10	Population-based 10-year event-free survival after radical prostatectomy for patients with prostate cancer in British Columbia. <i>Canadian Urological Association Journal</i> , 2015, 9, 409.	0.6	3
11	Regional dose metrics as predictors of biochemical failure and local recurrence after low-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2015, 14, 350-358.	0.5	5
12	Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity. <i>Brachytherapy</i> , 2015, 14, 342-349.	0.5	25
13	Patterns of Recurrence After Low-Dose-Rate Prostate Brachytherapy: A Population-Based Study of 2223 Consecutive Low- and Intermediate-Risk Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 745-751.	0.8	18
14	Prostate-Specific Antigen at 4 to 5 Years After Low-Dose-Rate Prostate Brachytherapy Is a Strong Predictor of Disease-Free Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 87-93.	0.8	54
15	Decline in acute urinary toxicity: A long-term study in 2011 patients with prostate brachytherapy within a provincial institution. <i>Brachytherapy</i> , 2014, 13, 46-52.	0.5	21
16	Late Urinary Side Effects 10 Years After Low-Dose-Rate Prostate Brachytherapy: Population-Based Results From a Multiphysician Practice Treating With a Standardized Protocol and Uniform Dosimetric Goals. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 570-578.	0.8	52
17	Incidence of Second Malignancies in Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy and Radical Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 934-941.	0.8	31
18	Pride or prejudice: Does Phoenix flatter radiation therapy?. <i>Brachytherapy</i> , 2014, 13, 299-303.	0.5	6

#	ARTICLE	IF	CITATIONS
19	Rebuttal to Drs Stone and Stock. <i>Brachytherapy</i> , 2014, 13, 44-45.	0.5	6
20	Whole prostate D90 and V100: A doseâ€response analysis of 2000 consecutive 125I monotherapy patients. <i>Brachytherapy</i> , 2014, 13, 32-41.	0.5	32
21	Populationâ€based 10â€year oncologic outcomes after lowâ€doseâ€rate brachytherapy for lowâ€risk and intermediateâ€risk prostate cancer. <i>Cancer</i> , 2013, 119, 1537-1546.	4.1	99
22	Rectal toxicity and rectal dosimetry in low-dose-rate 125I permanent prostate implants: A long-term study in 1006 patients. <i>Brachytherapy</i> , 2012, 11, 199-208.	0.5	66
23	Point: The relationship between postimplant dose metrics and biochemical no evidence of disease following low dose rate prostate brachytherapy: Is there an elephant in the room?. <i>Brachytherapy</i> , 2010, 9, 289-292.	0.5	18